PTPRC and neoplasm: FACS analysis showed that the increased tumor-associated CD8+ T cell numbers and the percentage of CD8+ in CD45+ were well maintained 4- and 10-weeks after drug withdrawal, and were not affected by S1PR modulator Fingolimod (Fig. 6B).